Epizyme Inc  

(Public, NASDAQ:EPZM)   Watch this stock  
Find more results for EPZM
17.60
-0.10 (-0.56%)
After Hours: 17.60 0.00 (0.00%)
Oct 17, 4:49PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 17.35 - 18.15
52 week 8.38 - 20.45
Open 17.80
Vol / Avg. 0.00/804,282.00
Mkt cap 1.19B
P/E     -
Div/yield     -
EPS -2.06
Shares 67.79M
Beta 2.22
Inst. own 85%
Nov 1, 2017
Q3 2017 Epizyme Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Sep 27, 2017
Epizyme Inc at Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology
Sep 11, 2017
Epizyme Inc at Morgan Stanley Healthcare Conference - Webcast
Sep 6, 2017
Epizyme Inc at Citi Biotech Conference - Webcast
Aug 16, 2017
Epizyme Inc at Wedbush PacGrow Healthcare Conference
Aug 4, 2017
Q2 2017 Epizyme Inc Earnings Release
Aug 4, 2017
Q2 2017 Epizyme Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin -280.24% -1376.45%
Operating margin -284.62% -1396.60%
EBITD margin - -1376.76%
Return on average assets -52.38% -46.86%
Return on average equity -69.27% -59.38%
Employees 112 -
CDP Score - -

Address

400 Technology Sq Ste 4
CAMBRIDGE, MA 02139-3584
United States - Map
+1-617-2295872 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Epizyme, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs). The Company develops small molecule inhibitors of other chromatin modifying proteins (CMPs). The Company's lead product candidate, tazemetostat, is a potent and selective inhibitor of the enhancer of zeste homolog 2 (EZH2) histone methyltransferases (HMT), an enzyme that plays an important role in various cancers. The Company is evaluating tazemetostat in a Phase II study in adults with relapsed or refractory non-Hodgkin lymphoma (NHL), and one Phase I study in children with molecularly defined solid tumors. The Company owns the global development and commercialization rights to tazemetostat outside of Japan.

Officers and directors

David M. Mott Independent Chairman of the Board
Age: 51
Bio & Compensation  - Reuters
Robert B. Bazemore Jr. President, Chief Executive Officer, Director
Age: 49
Bio & Compensation  - Reuters
Susan E. Graf Chief Business Officer, Principal Financial Officer
Age: 44
Bio & Compensation  - Reuters
Matthew Ros Chief Operating Officer
Age: 50
Bio & Compensation  - Reuters
Peter T.C. Ho M.D., Ph.D. Executive Vice President, Chief Medical Officer
Age: 55
Bio & Compensation  - Reuters
Suzanne Fleming Senior Vice President - Finance, Principal Accounting Officer, Treasurer
Age: 56
Bio & Compensation  - Reuters
Kevin T. Conroy Director
Age: 51
Bio & Compensation  - Reuters
Andrew R. Allen M.D. Ph.D. Independent Director
Age: 50
Bio & Compensation  - Reuters
Kenneth M. Bate Independent Director
Age: 66
Bio & Compensation  - Reuters
Carl S. Goldfischer M.D. Independent Director
Age: 58
Bio & Compensation  - Reuters